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Abstract
Background: Owing to the stigma associated with sexually transmitted infections, patients may
prefer to keep their illness private, and choose instead to try self-treatment remedies from the
internet. However, such remedies may prove hazardous if the sellers do not provide detailed
advice on adverse effects, or on avoiding transmission and re-infection. We conducted an internet
search to determine the availability of treatments for STIs and the nature of information provided
by vendors of these treatments.
Methods:  We conducted a systematic internet search using five different search engines in
February 2007. The search term included the words "self treatment" and the name of six different
common STIs. We visited the vendors' websites and recorded any information on the formulation,
adverse effects, cautions, and prevention of infection.
Results: We identified a total of 77 treatments from 52 different companies, most of which were
sold from the UK and US. The available remedies were predominantly for topical use and consisted
mainly of homeopathic remedies. Only a small proportion of the web-listed products gave details
on adverse effects, contraindications and interactions (22%, 25% and 9% respectively). Similarly,
web vendors seldom provided advice on treatment of sexual contacts (20% of chlamydia and 25%
of gonorrhea treatments) or on preventive measures (13%). Conversely, evidence of effectiveness
was claimed for approximately 50% of the products.
Conclusion: While treatments for certain STIs are widely available on the internet, purchasers of
such products may potentially suffer harm because of the lack of information on adverse effects,
interactions and contra-indications. Moreover, we consider the paucity of preventive health advice
to be a serious omission, thereby leading to patients being needlessly exposed to, and potentially
re-infected with the causative pathogens.
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Background
Although the incidence of sexually transmitted disease
(STIs) has decreased over the past few decades in Western
Europe, recent years have seen a reversal of this trend [1].
For instance, there has been an increase in notifications of
Chlamydia trachomatis, secondary syphilis, genital warts
and genital herpes in the UK over the past years [2].
One of the major barriers in the management of sexually
transmitted infections is the associated stigma that may
prevent patients from seeking professional medical care
[3-5]. While media campaigns may lead to enhanced gen-
eral awareness of STIs, patients who shun the spotlight
may turn to lay systems of care in search of a quick and
easy cure. Here, the internet can offer a sense of privacy,
making it a useful, confidential resource for information
in stigmatized conditions, and reaching subgroups that
may not normally be captured through other means [6].
Recent research has highlighted the widespread Internet
availability of self test kits for a number of conditions,
including Chlamydia [7]. The potentially easy access to
diagnostic tests and treatments from the privacy of one's
home may make the internet an appealing avenue for
patients seeking remedies for their STIs.
One of the major concerns regarding internet purchases is
whether the appropriate safeguards have been put in place
to protect the patient. Treatment of STIs is not a simple
one-off solution – the remedies will inevitably fail if users
are not advised on minimizing re-infection and concur-
rent treatment of sexual contacts. Moreover, licensed
drugs are tightly regulated and come with government
approved information leaflets that help patients to check
that the medication is indeed safe and suitable for them.
This may not be the case for Internet purchases.
As such, we surveyed the availability of treatments for
common STIs on the Internet, and evaluated the product
information and public health advice given by the ven-
dors of such treatments.
Methods
We conducted a systematic search of the internet using '
[infection] self treatment' as the search term, where [infec-
tion] was substituted by one of the following STIs: genital
warts, HPV, genital herpes, chlamydia, gonorrhea and
syphilis. There are a variety of search engines available for
the retrieval of information from the internet. To increase
the likelihood of finding treatments for STIs, we used five
search engines: Google™, Ask™, Yahoo!®, MSN® and Clusty.
The most popular of this is Google, which is reported to
cover 75% of the internet; the first four together power
95% of the internet searches in the UK [8]. Clusty was
added for completeness. The search was conducted in Feb-
ruary 2007.
Eighty percent of people searching the internet would
only use the first two pages retrieved by the search [9]. In
order to replicate this typical behavior, we opened all the
links on the first two pages retrieved by the search engine,
plus all the sponsored links on those pages. For Clusty, we
also explored the first two pages of all the relevant 'clus-
ters'. We visited websites that offered treatment of STIs
(with or without offering concurrent diagnostic tests) and
retrieved product data onto a database with predefined
fields (Table 1). We collected information on the type of
treatments, including its compounds if reported, the dose
and length of treatment, the cost, whether interactions,
contraindications or side effects were reported, and if
advice regarding prevention of transmission or treatment
of sexual partners was offered.
The key criteria for inclusion onto the database were that
the websites were selling products for the treatment of
STIs; we also included website that sold information
(rather than physical remedies) on how to treat the condi-
tions (i.e. e-books). We only researched the websites and
the products offered up to the point where payment was
required. On completion of the database, we aggregated
the collected data and descriptively summarized the gen-
eral characteristics of the available treatments.
Table 1: Data collected for each product.
• Product name
• Manufacturer (or company selling the product)
• Country where sold from
• Active component
• Formulation
• Price per item (smallest pack size)
• Side effects
• Contraindications
• Interactions
• Medical consultation/advice offered
• Partner treatment recommended
• Prevention adviceBMC Public Health 2007, 7:333 http://www.biomedcentral.com/1471-2458/7/333
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Results
A total of 77 products from a total of 52 companies were
identified in the search (Table 2). These products were
shipped from six different countries. The majority (61%)
were from companies based in the United States, followed
by the United Kingdom (17%). The cost of the smallest
pack for each of the treatments ranged from $14.95 to
$290 (mean $51.76). The average cost did not differed
significantly between the different STIs.
The types of active compounds present in the products
identified were: homeopathic (73%), mainly for genital
warts and herpes; antibiotics (8%) for the treatment of
Chlamydia and Gonorrhea; and some chemical com-
pounds (5%), like podophyllum and imiquimod for the
treatment of genital warts. Information on the active com-
pound was not available for 14%. Of the homeopathic
remedies two (for the treatment of herpes) contained
dilutions of viruses (including a variety of herpes viruses,
cytomegalovirus, Epstein Barr virus and poliomyelitis)
that claimed to stimulate natural immunity to clear the
infection. Two other websites offered e-books on proven
treatments of genital warts with remedies that could be
made with products home available; but there was not
enough information on the websites to determine the
exact nature of these products.
Overall, side effects were discussed in 22% of the prod-
ucts, contraindications in 25% and interactions with
other drugs in 9%. The reporting of these was better for
treatments of bacterial infections for which it was also
more likely that an online medical consultation was
offered or that advice to seek medical attention in case of
treatment failure would be given if treatment failed.
Where side effects were discussed this related to skin irri-
tation; also the commonest contraindication, when men-
tioned, was pregnancy and breastfeeding. However, in the
seven products where drug interactions were available
four were related to antibiotics in which a pre-treatment
form or some sort of virtual consultation was required.
Inversely, there were claims of beneficial properties in
almost 50% of the products, either by stating its effective-
ness or by referring to approval by a regulatory body or the
compliance with manufacturing regulations. Where stud-
ies were cited, these were hard to track down or referred to
empirical research. Testimonial from other patients was
widely used by most of the websites as a form of qualita-
tive evidence.
Recommendation that sexual partners should also be
treated or advice regarding prevention (e.g. use of con-
doms, abstinence while on treatment, testing for other
STI, etc.) was rarely given (13% had preventive messages).
Partner treatment was recommended in 20% of treat-
ments for chlamydia and 25% for gonorrhea (Table 2).
Discussion
The internet may provide a sense of privacy, as high-
lighted by behavioral research into stigmatized issues [6].
As a result people may turn to the internet to seek help for
a STI. In our study we identified many products on offer
Table 2: details of the products identified by the conditions treated (search conducted in February 2007).
Chlamydia Genital herpes Genital warts Gonorrhoea
Number of products 5 39 29 4
Treatment recommended by UK treatment guidelines [11–15] 3† 0 4 3†
Number of companies 4 20‡ 25‡ 3
Country (shipping from)
China - 1 (3%) 1 (3%) -
EU (unspecified) - 2 (5%) 1 (3%) -
India - 1 (3%) - -
New Zealand 1 (20%) 1 (3%) 1 (3%) -
UK 3 (60%) 3 (8%) 4 (14%) 3 (75%)
US 1 (20%) 29 (74%) 16 (55%) 1 (25%)
Not specified - 2 (5%) 6 (21%) -
Average (range) package cost§ 58.28 (19.95–87.89) 44.84 (14.95–290) 56.99 (15.95–229) 73.22 (39–107.42)
Side effects reported* 2 (40%) 6 (15%) 7 (24%) 2 (50%)
Contraindications reported* 2 (40%) 6 (15%) 9 (31%) 2 (50%)
Interactions reported* 2 (40)% 2 (5%) 1 (3%) 2 (50%)
Consultation offered* 3 (60%) 13 (33%) 6 (21%) 3 (75%)
Recommended medical advice* 3 (60%) 7 (18%) 5 (17%) 3 (75%)
Partner treatment* 1 (20%) - 2 (7%) 1 (25%)
Prevention advice* 2 (40%) 2 (5%) 4 (14%) 2 (50%)
Claims of effectiveness* 3 (60%) 24 (62%) 9 (31%) 2 (50%)
* Value is number and percentage of products; ‡ each product sold on e-bay is counted as belonging to a separate company; §costs are given in USD 
(USD:GBP = 0.512/USD:EURO = 0.763); † treatment consists of an unspecified antibioticBMC Public Health 2007, 7:333 http://www.biomedcentral.com/1471-2458/7/333
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for symptomatic conditions with topical manifestations,
such as genital warts and herpes. Conversely, there were
far fewer treatments available for conditions such as
Chlamydia or Gonorrhea infection that may not be obvi-
ous to the person suffering them. This may be because
these conditions require specific testing to identify the
causal agent or because a larger proportion of patients
may be asymptomatic [10].
The cost of treatments on offer ranged from $14.95 to
$290, making some of the treatments relatively affordable
in comparison with the current cost of a prescription or
the actual cost of some of the treatments recommended
by accepted treatment guidelines [11-15]. On the other
hand, some treatments were relatively expensive, which
suggest that treatment cost may not be an issue for some.
Active components of the different treatment varied con-
siderably. These were mainly homeopathic or herbal rem-
edies. Although there is some empirical evidence that
compounds like lemon balm and lysine may have antivi-
ral properties [16,17], there is not enough information in
the websites that we identified to judge whether treat-
ments are effective or not. Some vendors provided exam-
ples of clinical studies, but the cited evidence was limited
to in-vitro research in the best cases, or poor quality or
doubtful studies in others. None of the websites offered
information about well conducted randomized control
trials in humans. While we do have serious misgivings
around the lack of evidence on efficacy, we are also
equally concerned at the lost opportunity for essential
public health advice on prevention and control of trans-
mission, the absence of which will negate the expected
benefits on any treatment.
There is evidence that co-infection with more than one STI
can occur [18]. Generally we found that no advice was
given to test for concomitant infections. Also worryingly,
most of the vendors' websites we identified did not dis-
play information on prevention of transmission, such as
use of condoms or abstinence while on treatment. Nor
did they recommend notification, testing and treatment
of sexual partners. The glaring lack of advice on avoiding
re-infection, and treatment of contacts means that some
of these remedies are doomed to fail. Indeed, this may
contribute to greater individual hazard, and risk to the
public from greater spread of the STIs.
The majority of the products were from companies based
in the US or the UK, where there is good regulation of
drugs and therapeutics. However, as some of the products
sold through the internet could be classed as herbal
extracts, topical applications or even beauty products,
they may be overlooked by regulations requiring a pre-
scription from a qualified health professional. The lack of
information on side effects, contraindications or interac-
tion is in contrast with the many unsubstantiated claims
of effectiveness; this may mislead potential buyers to
believe these treatments are better than recommended
pharmacological treatments. Moreover, the absence of
trial data on these products means that patients may inad-
vertently be paying for, and using products which are
unsafe or unsuitable for them.
This study is limited by the lack of information on how
many people access and buy products to self treat STIs via
the internet. We are only able to comment on the amount
of products and their affordability and hence speculate
that a market exists for these products. Anecdotally, dur-
ing the time that we were conducting the search a total of
21 items of four different products we identified for geni-
tal warts or genital herpes were sold through eBay;
whereas the number of people that had viewed each prod-
uct on sale ranged between 61 and 263 (based on values
on the eBay counter for each page). Of the 4 products sold
through a single eBay trader, there were at least 29 con-
firmed buyers over the past 90 days who left positive feed-
back. This is likely to be a significant underestimate
though as purchasers of such products may prefer not
leave their details on the seller's feedback page.
Also, this study only focuses on one source of alternative
treatment for STIs (i.e. the internet) and it does not
address questions regarding accessibility and usage of
these alternative sources. While we did not actually pur-
chase any products, other researchers have reported suc-
cess in buying both prescription drugs and alternative
therapies from Internet merchants[19].
Unfortunately, we are unable to explain the characteristics
of people that may access treatment for STIs in this way,
but merely speculate that if treatments are being sold and
bought on the internet means that there are people willing
to use alternative ways of accessing treatment. It is possi-
ble that people who use the internet for such therapies are
already well-versed with preventative measures and may
be purchasing the treatment for both themselves and their
partners. Conversely, the lack of information from web
traders on prevention may well be a cynical way of ensur-
ing repeat visits from their customer base. Further research
may be needed to determine the role that alternative ther-
apies and lay systems play in the treatment of STIs and
therefore be able to asses the overall impact that these
may have in their epidemiology and transmission control.
Regulatory agencies' websites in the UK and US warn con-
sumers of the problems of purchasing treatments through
the internet and of the doubtful quality of some of the
products [20,21]. It has also been suggested that doctors
need to advise their patients against using drugs boughtBMC Public Health 2007, 7:333 http://www.biomedcentral.com/1471-2458/7/333
Page 5 of 5
(page number not for citation purposes)
on the internet [22]. We argue that some patients with
STIs may not even present to a doctor at all. Indeed, gov-
ernment information campaigns that increase the aware-
ness of STIs may potentially increase the market for STI
remedies on the Internet, given the stigmatized nature of
STIs and the relative convenience of online purchases.
The marketing and professional regulations of some of
these products or companies may not be as tight as those
provided by registered pharmaceutical companies and the
medical establishment, thus resulting in lack of informa-
tion about side-effects, contraindications or interactions.
Furthermore, because of the lack of contact with health
care professionals, a valuable opportunity for patient edu-
cation and prevention advice is lost.
Conclusion
As regulation of vendors on the Internet is unlikely to ever
be successful, we propose that the public should be edu-
cated on the dangers of using self-treatment of STIs, par-
ticularly where preventative measures are essential in
stopping re-infection. Government agencies could explore
the possibility of using the same search engines that are
used by potential customers of these products, ensuring
that similar searches also return prominent links to pro-
motional sites warning of the dangers and giving appro-
priate preventive advice.
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